Company Filing History:
Years Active: 2014
Title: The Innovative Contributions of Vieroslava Gurunian
Introduction
Vieroslava Gurunian is a notable inventor based in Allamuchy, NJ (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target central nervous system disorders. With a focus on innovation, Gurunian has been instrumental in advancing medical science through her research and inventions.
Latest Patents
Gurunian holds a patent for "Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof." This invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones. The compounds developed are modulators of metabotropic glutamate receptors (mGluR), particularly the mGluR2 receptor. These compounds are useful as pharmaceutical agents in the treatment and prevention of various central nervous system disorders, including neurodegenerative conditions, psychoses, anxiety, and sleep disorders.
Career Highlights
Gurunian is currently employed at Sanofi, a leading global biopharmaceutical company. Her work at Sanofi has allowed her to collaborate with other talented professionals in the field. She has been recognized for her innovative approach to drug development and her commitment to improving patient outcomes.
Collaborations
Gurunian has worked alongside notable colleagues such as Bin Cao and Sathapana Kongsamut. These collaborations have fostered a creative environment that encourages the exchange of ideas and the advancement of research in pharmaceuticals.
Conclusion
Vieroslava Gurunian's contributions to the field of pharmaceuticals exemplify the impact of innovation in medicine. Her patented work on oxazolopyrimidinones showcases her dedication to addressing critical health issues. Through her career at Sanofi and her collaborations, Gurunian continues to pave the way for future advancements in the treatment of central nervous system disorders.